VOR · Vor Biopharma Inc.
$18.74
+0.05 (+0.27%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.10B
Shares
59.16M
Volume · Oct 5
648.62K
Avg daily vol (3M)
1.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.69
Open$18.09
Day$18.09–18.99
52W close$6.86–37.46
Avg vol 30d1.1M
Short int7.9M · 13.4% float · 11.1d
Short vol58%
DataFeb 2021–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$627.78M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 961.4%
FCF yield
-12.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$466.13M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+767.0%
Year over year · more shares
Price change (1Y)
-49.0%
Trailing year
Short interest
13.4%
Latest settlement · 11.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
−15%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
39%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
+17%
trailing
YTD return
+43%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
1 of 102 funds reported for Sep 30 · net +728 sh shares · +1 new
Insider flow
Distributing
Net -$4.2K over 90 days · 100% sells
Short interest
Rising
13.36% of float · ▲ +3.1% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
−107%
Y/Y
Free cash flow
$-143.7M
Quant / Vol
risk profile
Volatility
106%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
−15%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
39%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $22 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
1 of 102 funds reported for Sep 30 · net +728 sh shares · +1 new
Insider flow
Distributing
Net -$4.2K over 90 days · 100% sells
Short interest
Rising
13.36% of float · ▲ +3.1% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $19 · 39%
Range high $37
vs 200-day avg +12%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VOR
this stock
Vor Biopharma Inc.
|
$1.10B | +42.9% | — | — | 13.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VOR | +0.9% | -22.9% | +17.0% | -2.0% | +42.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +1.1% | -22.4% | +4.9% | -3.0% | +30.0% |